IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 1(6):502-509;2008

Original Article
Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific

Qihui “Jim” Zhai, Daniel Gustavo Rosen, Karen Lu and Jinsong Liu

Department of Pathology, Methodist Hospital, Houston Texas; and the Departments of Pathology and 3Gynecology Oncology, The University of
Texas M. D. Anderson Cancer Center, Houston, Texas

Received 27 Dec 2007; accepted with revision 14 Jan 2008; available online 31 Jan 2008

grade, disease stage, familial history of cancer and patient survival. We stained an ovarian carcinoma tissue microarray consisting of
semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein
formalin-fixed, paraffin-embedded tissue samples from 322 patients with an anti-hMSH6 antibody and scored the results was noted in 20
semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein in 1 of
14 malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated was noted
in 20 of 230 serous carcinomas (8.7%), in 7 of 16 clear cell carcinomas (43.7%), in 4 of 34 endometrioid carcinomas (11.7%), carcinomas.
Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with in 1 of 14
malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated carcinomas.
Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with clear cell,
mucinous and endometrioid carcinoma histology (P<0.007). These findings indicate that loss of hMSH6 expression in ovarian carcinoma is
more common in certain histologic subtypes, particularly in clear cell, endometrioid, and mucinous carcinoma, suggesting survival and was not
associated with disease stage, tumor grade, patient age or family history of cancer. (IJCEP712005).